Cytokines and cognitive function in mice

NeuroSignals

Volumn 7, Issue 1, 1998, Pages 45-54

  Bianchi, Mauro ^a   Sacerdote, Paola ^a   Panerai, Alberto E ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Granulocyte macrophage colony stimulating factor; Hippocampus; Interleukin 1; Interleukin 2; Interleukin 6; Neurotransmitter amino acids; Passive avoidance; Scopolamine induced amnesia

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; SCOPOLAMINE;

AMINO ACID BRAIN LEVEL; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; CONTROLLED STUDY; HIPPOCAMPUS; IMMUNE SYSTEM; MALE; MOUSE; NERVOUS SYSTEM; NEUROMODULATION; NONHUMAN; PASSIVE AVOIDANCE;

AMNESIA; ANIMALS; AVOIDANCE LEARNING; COGNITION; CYTOKINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MICE; MICE, INBRED STRAINS; RECOMBINANT PROTEINS; SCOPOLAMINE;

ANIMALIA;

EID: 0031752276     PISSN: 1424862X     EISSN: 14248638     Source Type: Journal    
DOI: 10.1159/000014527     Document Type: Article

References (44)

1. Black PH: Immune system-central nervous system interactions: Effect and immunomodulatory consequences of immune system mediators on the brain. Antimicrob Agents Chemoter 1994;38:7-12.
2. Plata-Salaman CR: Immunoregula-tors in the nervous system. Neurosci Biobehav Rev 1991;15:185-215.
3. Rothwell NJ: Functions and mechanisms of interleukin-1 in the brain. Trends Pharmacol Sci 1991; 12: 430-436.
4. Farrar KL, Kilian PL, Ruff MR, Hill JM, Pert CB: Visualization and characterization of interleukin-1 receptors in the brain. J Immunol 1987;139:459-463.
5. Katsuki H, Nakai S, Hirai Y, Akaji K, Kiso Y, Satoh M: Interleukin-1p inhibits long-term potentiation in the CA3 region of mouse hippocampal slices. Eur J Pharmacol 1990; 181:323-326.
6. Rada P, Mark GP, Vitek MP, Mangano RM, Blume AJ, Beer B, Hoebel BG: Interleukin-ip decreases acetylcholine measured by microdialysis in the hippocampus of freely moving rats. Brain Res 1991;550:287-290.
7. Cassel JC, Jeltsch H: Serotonergic modulation of cholinergic function in the central nervous system: Cognitive implications. Neuroscience 1995;69:1-41.
8. Besedowsky HO, Del Rey A: Immune-neuro-endocrine interactions: Facts and hypotheses. Endocr Rev 1996;17:64-102.
9. Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H, Greenberg AH: Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 1994;643:40-49.
10. Hüll M, Strauss S, Berger M, Volk B, Bauer J: The participation of interleukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer’s disease. Behav Brain Res 1996;78: 37-41.
11. Merril JE, Jonakait GM: Interactions of the nervous and immune systems in development, normal brain homeostasis, and disease. FASEB J 1995;9:611-618.
12. Nistico’ G: Communications among central nervous system, neuroendocrine and immune systems: Interleukin-2. Prog Neurobiol 1993;40:463-475.
13. Denicoff KD, Ribinow DR, Papa MZ, Simpson L, Seipp LA, Lotze MT, Chang AE, Rosenstein D, Rosenberg SA: The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated cells. Ann Intern Med 1987; 107: 293-300.
14. Rosenberg SA: Immunotherapy of cancer using interleukin-2: Current status and future prospects. Immunol Today 1988;9:58-62.
15. Nemni R, Iannaccone S, Quattrini A, Smirne S, Sessa M, Lodi M, Erminio C, Canal N: Effect of chronic treatment with recombinant interleukin-2 on the central nervous system of adult and old mice. Brain Res 1992;591:248-252.
16. Lieschke GJ, Burgess AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 1992;327:28-34.
17. Vial T, Descotes J: Clinical toxicity of cytokines used as haemopoietic growth factors. Drug Saf 1995;13: 371-406.
18. Bianchi M, Panerai AE: Reversal of scopolamine-induced amnesia by the GABAB receptor antagonist CGP 35348 in the mouse. Cogn Brain Res 1993;1:135-136.
19. Sivilotti L, Nistri A: GABA receptor mechanisms in the central nervous system. Prog Neurobiol 1991;36: 35-92.
20. Collingridge GL, Lester RA: Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol Rev 1989;41:143-210.
21. a interferes with scopolamine-induced amnesia in mice. Cogn Brain Res 1993; 1: 257-259.
22. Bianchi M, Ferrario P, Zonta N, Panerai AE: Effects of interleukin-1p and interleukin-2 on amino acids levels in mouse cortex and hippocampus. Neuroreport 1995;6:1689-1692.
23. Bianchi M, Ferrario P, Clavenna A, Panerai AE: Interleukin-6 affects scopolamine-induced amnesia, but not brain amino acid levels in mice. Neuroreport 1997;8:1775-1778.
24. Bianchi M, Panerai AE: Interleukin-2 enhances scopolamine-induced amnesia and hyperactivity in the mouse. Neuroreport 1993;4:1046-1048.
25. Grant SM, Heel RC: Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). A review of its pharmacological properties and prospective role in the management of myelosuppression. Drugs 1992;43:516-560.
26. Lindemann A, Riedel D, Oster W, Meuerr SC, Blohm D, Mertelsmann RH, Herrmann F: Granulocyte macrophage colony-stimulating factor induces interleukin-1 production by human polymorphonuclear neutrophils. J Immunol 1988;140:837-839.
27. Bianchi M, Sacerdote P, Panerai AE: Peripherally administered GM-CSF interferes with scopolamine-induced amnesia in mice: Involvement of interleukin-1. Brain Res 1996;729:285-288.
28. Bianchi M, Clavenna A, Bondiolotti GP, Ferrario P, Panerai AE: Peripherally administered GM-CSF affects hypothalamic neurotransmitters levels in mice: Involvement of interleukin-1. Neuroreport 1997;8:3587-3590.
29. Royston MC, Rothwell NJ, Roberts GW: Alzheimer’s disease: Pathology to potential treatments? Trends Pharmacol Sci 1992;13:131-133.
30. Hickie I, Lloyd A: Are cytokines associated with neuropsychiatric syndromes in humans? Int J Immuno-pharmacol 1995;17:677-683.
31. Gibertini M, Newton C, Klein TW, Friedman H: Legionella pneumophila-induced visual learning impairment reversed by anti-interleukin-1 beta. Proc Soc Exp Biol Med 1995;210:7-11.
32. Kent S, Bluthe RM, Kelley KW, Dantzer R: Sickness behavior as a new target for drug development. Trends Pharmacol Sci 1992; 13:2428.
33. Auberg A, Vega C, Dantzer R, Goo-dall G: Pyrogens specifically disrupt the acquisition of a task involving cognitive processing in the rat. Brain Behav Immun 1995;9:129-148.
34. Watkins LR, Maier SF, Goehler LE: Cytokine-to-brain communication: A review and analysis of alternative mechanisms. Life Sci 1995;57: 1011-1026.
35. Lee JH, El-Kakahany EE: Heterogeneity of binding of muscarinic receptors antagonists in rat brain homogenates. J Pharmacol Exp Ther 1985;233:707-714.
36. Hanish U, Seto D, Quirion R: Modulation of hippocampal acetylcholine release: A potent central action of interleukin-2. J Neurosci 1993; 13:3368-3374.
37. Sarter M: Taking stock of cognition enhancers. Trends Pharmacol Sci 1991;12:456-461.
38. Matthies H: Neurobiological aspects of learning and memory. Annu Rev Psychol 1983;40:381-404.
39. Galliani G, Cesana R, Barzaghi F: Reversal of scopolamine-induced amnesia by arecoline. Med Sci Res 1987;15:313-314.
40. Ban E, Milon G, Prudhomme N, Fillion G, Haour F: Receptors for interleukin-1 (alpha and beta) in mouse brain: Mapping and neuronal localization in hippocampus. Neuroscience 1991;43:21-30.
41. Gadient RA, Otten U: Expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) mRNAs in rat brain during postnatal development. Brain Res 1994;637:10-14.
42. Chang Y, Albright S, Lee F: Cytokines in the central nervous system: Expression of macrophage colony stimulating factor and its receptor during development. J Neuroimmu-nol 1994;52:9-17.
43. Dunn AJ, Antoon M, Chapman Y: Reduction of exploratory behavior effects of peripherally injected interleukin-1 involves brain corticotropin-releasing-factor. Brain Res Bull 1991;26:539-542.
44. Fent K, Zbinden G: Toxicity of interferon and interleukin. Trends Pharmacol Sci 1987;8:100-105.